Stockscreener 앱 받기
111.51
0.11%
-0.12
시간 외 거래:
111.51
전일 마감가:
$111.63
열려 있는:
$113.17
하루 거래량:
1.72M
Relative Volume:
0.78
시가총액:
$31.51B
수익:
$7.07B
순이익/손실:
$1.29B
주가수익비율:
24.59
EPS:
4.5355
순현금흐름:
$993.00M
1주 성능:
-3.09%
1개월 성능:
-11.37%
6개월 성능:
-9.52%
1년 성능:
-4.96%
1일 변동 폭
$111.02
$113.65
1주일 범위
$110.89
$117.03
52주 변동 폭
$96.43
$160.27
애질런트 테크놀로지스 Stock (A) Company Profile
명칭
Agilent Technologies Inc
전화
(408) 345-8886
주소
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
A
Agilent Technologies Inc
|
111.51 | 31.55B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 176.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 131.71B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.48B | 4.30B | 1.06B | 1.04B | 13.08 |
|
WAT
Waters Corp
|
286.57 | 27.79B | 3.17B | 642.63M | 516.49M | 10.77 |
애질런트 테크놀로지스 Stock (A) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 개시 | HSBC Securities | Buy |
| 2026-01-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-12-15 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-12-09 | 개시 | Goldman | Buy |
| 2025-12-02 | 개시 | Morgan Stanley | Overweight |
| 2025-10-08 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-08 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-10 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-04-05 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-05-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | Citigroup | Neutral |
| 2023-05-24 | 재확인 | Credit Suisse | Outperform |
| 2023-05-24 | 재확인 | Evercore ISI | Outperform |
| 2023-05-24 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | 재확인 | Robert W. Baird | Outperform |
| 2023-05-24 | 재확인 | SVB Securities | Outperform |
| 2023-05-24 | 재확인 | Stifel | Hold |
| 2023-05-24 | 재확인 | TD Cowen | Outperform |
| 2023-05-24 | 재확인 | Wells Fargo | Overweight |
| 2023-05-11 | 개시 | Barclays | Equal Weight |
| 2023-01-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2022-07-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | 재확인 | BofA Securities | Buy |
| 2022-02-23 | 재확인 | Citigroup | Buy |
| 2022-02-23 | 재확인 | Cowen | Outperform |
| 2022-02-23 | 재확인 | Evercore ISI | Outperform |
| 2022-02-23 | 재확인 | Stifel | Hold |
| 2022-02-23 | 재확인 | Wells Fargo | Overweight |
| 2021-11-23 | 재확인 | BofA Securities | Buy |
| 2021-11-23 | 재확인 | Cowen | Outperform |
| 2021-11-23 | 재확인 | Stifel | Hold |
| 2021-03-18 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-12-02 | 개시 | Goldman | Buy |
| 2020-11-25 | 업그레이드 | UBS | Neutral → Buy |
| 2020-11-17 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | 개시 | Atlantic Equities | Neutral |
| 2020-08-19 | 재확인 | BofA Securities | Neutral |
| 2020-08-19 | 재확인 | Citigroup | Neutral |
| 2020-08-19 | 재확인 | Jefferies | Buy |
| 2020-08-19 | 재확인 | Robert W. Baird | Outperform |
| 2020-08-19 | 재확인 | SVB Leerink | Outperform |
| 2020-08-19 | 재확인 | Stifel | Hold |
| 2020-08-19 | 재확인 | Wells Fargo | Overweight |
| 2020-02-24 | 다운그레이드 | Needham | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-26 | 재확인 | Needham | Buy |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-07-16 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | 다운그레이드 | Barclays | Overweight → Equal Weight |
모두보기
애질런트 테크놀로지스 주식(A)의 최신 뉴스
Deal Dispatch: Papa John's May Go Private, Shell Buys Jiffy Lube, Meta Acquires Moltbook - Benzinga
Magnetar Financial LLC Decreases Holdings in Agilent Technologies, Inc. $A - MarketBeat
Schroder Investment Management Group Buys 75,796 Shares of Agilent Technologies, Inc. $A - MarketBeat
Agilent Technologies, Inc. $A Shares Purchased by Natixis Advisors LLC - MarketBeat
Preventive Control Of Sequencing Through The Insert With The Agilent 5200 Fragment Analyzer System - Bioprocess Online
Agilent Expands CDMO Role With Advanced Therapeutics As Shares Lag Targets - simplywall.st
Agilent Technologies, Inc. (A) price target cut to $155 at Baird - MSN
Vestcor Inc Sells 10,204 Shares of Agilent Technologies, Inc. $A - MarketBeat
Mackenzie Financial Corp Buys 324,461 Shares of Agilent Technologies, Inc. $A - MarketBeat
Agilent unifies CDMO capabilities across Canada and United States - BioSpectrum India
Legal & General Group Plc Raises Position in Agilent Technologies, Inc. $A - MarketBeat
Korea Investment CORP Has $12.95 Million Stake in Agilent Technologies, Inc. $A - MarketBeat
Agilent launches unified CDMO business combining US, Canada units - Investing.com India
Blair William & Co. IL Decreases Holdings in Agilent Technologies, Inc. $A - MarketBeat
Lab chromatographs are quietly getting an AI upgrade in the US - AD HOC NEWS
Agilent Launches Advanced Therapeutics CDMO Solution for US and Canada - Contract Pharma
Agilent’s Biocare Deal Reshapes Pathology Presence As Shares Lag Targets - simplywall.st
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States - BioSpace
Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More - AOL.com
Agilent Technologies, Inc. $A Shares Sold by Swiss National Bank - MarketBeat
Agilent launches unified CDMO division across Canada and United States - StreetInsider
Lab Chromatographs Are Quietly Getting Smarter. Here Is Why It Matters - AD HOC NEWS
Jim Cramer on Agilent Technologies: “I Don’t Think You Need It” - Yahoo Finance
Agilent Technologies, Inc. $A Shares Sold by Russell Investments Group Ltd. - MarketBeat
Agilent Bets On Pathology Innovation With Biocare Acquisition - Yahoo Finance
Agilent snaps up pathology firm Biocare Medical for $950 million - malaysiasun.com
Is Agilent Technologies Stock Underperforming the S&P 500? - Barchart.com
Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy - CHEManager
Van ECK Associates Corp Sells 10,815 Shares of Agilent Technologies, Inc. $A - MarketBeat
Ceredex Value Advisors LLC Makes New $24.39 Million Investment in Agilent Technologies, Inc. $A - MarketBeat
Why Agilent Technologies Just Paid $950 Million For Biocare Medical (NYSE:A) - Seeking Alpha
First Trust Advisors LP Increases Stock Position in Agilent Technologies, Inc. $A - MarketBeat
Bank of America Maintains Neutral on Agilent Technologies (A) March 2026 - Meyka
Agilent to buy Biocare Medical from Excellere and GHO Capital - pehub.com
Agilent Technologies: $950 Million Acquisition Of Pathology Diagnostics Company Biocare Medical - Pulse 2.0
Agilent Technologies to acquire Biocare Medical for $950 million - The American Bazaar
Agilent Technologies to Acquire Biocare Medical in $950 Million Deal - Clinical Lab Products
Why Agilent Stock Is Slipping Premarket Today - Stocktwits
Agilent to Acquire Biocare Medical in $950 Million All-Cash Deal - TradingView
Sullivan & Cromwell Advises Agilent On $950M Biocare Buy - Law360
Agilent to buy Biocare Medical for $950M - Healthcare Dive
Agilent Technologies to acquire Biocare Medical in $950m deal - Medical Device Network
Agilent buys Biocare for $950M - BioWorld MedTech
BofA reiterates Agilent stock rating on Biocare acquisition - Investing.com
Agilent stock rises on $950M Biocare Medical acquisition - Investing.com South Africa
Agilent expands pathology portfolio with acquisition of Biocare Medical for $950 M - BioSpectrum India
Agilent to acquire Biocare Medical in $950 million all-cash deal - PharmaLive
Sienna Gestion Sells 26,245 Shares of Agilent Technologies, Inc. $A - MarketBeat
Victory Capital Management Inc. Boosts Stake in Agilent Technologies, Inc. $A - MarketBeat
Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip - Investing.com
Agilent to acquire Biocare Medical for $950M, expanding pathology portfolio - MSN
애질런트 테크놀로지스 (A) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
1.29%
자본화:
|
볼륨(24시간):